C12N 2795/14011
Ssdna bacteriophages
Official title: ssDNA Bacteriophages
C12N2795/14011 (Ssdna bacteriophages) appears on 183 US grants and 251 published applications in this corpus.
Search patents in C12N- Granted patents
- 183
- Published applications
- 251
- Assignees
- 150
- Inventors
- 519
- Latest grant
- 12 May 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1986 | 1 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 1 | 0 |
| 1991 | 0 | 0 |
| 1992 | 1 | 0 |
| 1993 | 2 | 0 |
| 1994 | 1 | 0 |
| 1995 | 2 | 0 |
| 1996 | 5 | 0 |
| 1997 | 3 | 0 |
| 1998 | 10 | 0 |
| 1999 | 1 | 0 |
| 2000 | 5 | 0 |
| 2001 | 3 | 1 |
| 2002 | 5 | 3 |
| 2003 | 5 | 10 |
| 2004 | 0 | 8 |
| 2005 | 4 | 6 |
| 2006 | 7 | 5 |
| 2007 | 2 | 6 |
| 2008 | 1 | 6 |
| 2009 | 2 | 7 |
| 2010 | 3 | 9 |
| 2011 | 3 | 8 |
| 2012 | 1 | 7 |
| 2013 | 8 | 6 |
| 2014 | 3 | 10 |
| 2015 | 6 | 8 |
| 2016 | 6 | 14 |
| 2017 | 8 | 7 |
| 2018 | 7 | 15 |
| 2019 | 9 | 20 |
| 2020 | 15 | 11 |
| 2021 | 14 | 21 |
| 2022 | 7 | 11 |
| 2023 | 10 | 13 |
| 2024 | 8 | 17 |
| 2025 | 11 | 10 |
| 2026 | 3 | 12 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12N 2795/14111InoviridaeIndexing code150
- C12N 2795/14041Use of virus, viral particle or viral elements as a vectorIndexing code16
- C12N 2795/14211MicroviridaeIndexing code15
- C12N 2795/14022New viral proteins or individual genes, new structural or functional aspects ofIndexing code14
- C12N 2795/14051Methods of production or purification of viral materialIndexing code3
- C12N 2795/14021Viruses as suchIndexing code2
- C12N 2795/14032Use of virus as therapeutic agent, other than vaccineIndexing code2
- C12N 2795/14031Uses of virus other than therapeutic or vaccineIndexing code1
All 14 subgroupsShow fewer
- C12N 2795/14034Use of virus or viral component as vaccineIndexing code1
- C12N 2795/14023Virus like particles [vlp]Indexing code0
- C12N 2795/14033Use of viral protein as therapeutic agent other than vaccineIndexing code0
- C12N 2795/14061Methods of inactivation or attenuationIndexing code0
- C12N 2795/14071Demonstrated in vivo effectIndexing code0
- C12N 2795/14088For redistributionIndexing code0
Recent patents
- Modular phage vector platform for sonodynamic therapy12 May 2026US 12,622,964 B2Alma Mater Studiorum - Università di Bologna
- Methods and compositions for efficient delivery of nucleic acids and rna-based antimicrobials21 Apr 2026US 12,606,834 B2North Carolina State University
- Propagator cells and methods for propagating phage, in particular for delivering CRISPR-Cas components via probiotic organisms6 Jan 2026US 12,516,297 B2SNIPR Technologies Limited
- Antibacterial phage, therapeutic composition, bactericidal agent, food, bacteria identification kit, therapeutic composition manufacturing method, bacteria elimination method, bacteria identification method, and animal therapeutic method23 Dec 2025US 12,502,413 B2Jichi Medical University
- M13 phage based gene therapy platform4 Nov 2025US 12,458,674 B2Massachusetts Institute of Technology
- Engineered bacteriophage particle and method of gene therapy by using same8 Oct 2026US 2026/0308626 A1Academia Sinica
- Microporous carbon nanofibers27 Aug 2026US 2026/0253906 A1Massachusetts Institute of Technology
- Components for genomic editing13 Aug 2026US 2026/0234657 A1Kano Therapeutics Inc.
- Methods and compositions for targeted delivery of therapeutics11 Jun 2026US 2026/0158147 A1Manifold Biotechnologies, Inc.
- Targeted genome modification using circular single-stranded dna28 May 2026US 2026/0146261 A1Full Circles Therapeutics, Inc.
Most cited
By later US patents
- Directed evolution of novel binding proteins2,450US 5,223,409 AProtein Engineering Corporation · 1993
- Viruses expressing chimeric binding proteins1,136US 5,403,484 AProtein Engineering Corporation · 1995
- Directed evolution of novel binding proteins1,057US 5,571,698 AProtein Engineering Corporation · 1996
- Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants660US 5,750,373 AGenentech, Inc. · 1998
- Surface expression libraries of heteromeric receptors586US 5,698,426 AIxsys, Inc. · 1997